Sequent Scientific Limited (SEQUENT.BO)
INR 136.85
(8.18%)
INR 136.85
(8.18%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 15.4 Billion INR | 0.74% |
| 2022 | 15.29 Billion INR | 5.39% |
| 2021 | 14.5 Billion INR | 4.19% |
| 2020 | 13.92 Billion INR | -4.79% |
| 2019 | 14.62 Billion INR | 5.39% |
| 2018 | 13.87 Billion INR | 3.36% |
| 2017 | 13.42 Billion INR | -29.5% |
| 2016 | 19.04 Billion INR | 24.64% |
| 2015 | 15.28 Billion INR | 52.01% |
| 2014 | 10.05 Billion INR | 61.43% |
| 2013 | 6.22 Billion INR | 6.22% |
| 2012 | 5.86 Billion INR | 7.11% |
| 2011 | 5.47 Billion INR | 24.77% |
| 2010 | 4.38 Billion INR | 14.85% |
| 2009 | 3.81 Billion INR | 49.49% |
| 2008 | 2.55 Billion INR | 154.66% |
| 2007 | 1 Billion INR | 101.37% |
| 2006 | 498.25 Million INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 15 Billion INR | 0.0% |
| 2023 Q4 | 15.4 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 15.4 Billion INR | 0.74% |
| 2022 FY | 15.29 Billion INR | 5.39% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 14.93 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 15.29 Billion INR | 0.0% |
| 2021 Q2 | 14.39 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 14.5 Billion INR | 4.19% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 14.5 Billion INR | 0.0% |
| 2020 Q4 | 13.92 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 13.92 Billion INR | -4.79% |
| 2020 Q2 | 16.01 Billion INR | 0.0% |
| 2019 FY | 14.62 Billion INR | 5.39% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 14.62 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 14.3 Billion INR | 0.0% |
| 2018 Q4 | 13.87 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 13.87 Billion INR | 3.36% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q2 | 13.62 Billion INR | 0.0% |
| 2017 Q2 | 17.47 Billion INR | 0.0% |
| 2017 FY | 13.42 Billion INR | -29.5% |
| 2017 Q4 | 13.42 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 FY | 19.04 Billion INR | 24.64% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 18.19 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 19.04 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 15.28 Billion INR | 0.0% |
| 2015 Q2 | 11.76 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 15.28 Billion INR | 52.01% |
| 2014 FY | 10.05 Billion INR | 61.43% |
| 2014 Q2 | 8.16 Billion INR | 0.0% |
| 2014 Q4 | 10.05 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 FY | 6.22 Billion INR | 6.22% |
| 2013 Q4 | 6.22 Billion INR | 0.0% |
| 2012 Q2 | 9.57 Billion INR | 0.0% |
| 2012 Q4 | 5.86 Billion INR | 0.0% |
| 2012 FY | 5.86 Billion INR | 7.11% |
| 2011 FY | 5.47 Billion INR | 24.77% |
| 2010 FY | 4.38 Billion INR | 14.85% |
| 2009 FY | 3.81 Billion INR | 49.49% |
| 2008 FY | 2.55 Billion INR | 154.66% |
| 2007 FY | 1 Billion INR | 101.37% |
| 2006 FY | 498.25 Million INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 76.102% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 96.582% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 45.959% |
| Granules India Limited | 55.2 Billion INR | 72.099% |
| Indoco Remedies Limited | 21.44 Billion INR | 28.178% |
| Achyut Healthcare Limited | 309.52 Million INR | -4876.654% |
| Ajanta Pharma Limited | 46.38 Billion INR | 66.791% |
| Alkem Laboratories Limited | 155.74 Billion INR | 90.11% |
| Alpa Laboratories Limited | 1.82 Billion INR | -743.484% |
| Brooks Laboratories Limited | 904.45 Million INR | -1603.109% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -42.889% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -101.324% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | -26.899% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 96.025% |
| Eris Lifesciences Limited | 70.48 Billion INR | 78.147% |
| FDC Limited | 24.68 Billion INR | 37.588% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 89.272% |
| Gufic Biosciences Limited | 10.92 Billion INR | -40.991% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -32.21% |
| Ipca Laboratories Limited | 111.01 Billion INR | 86.124% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -609.599% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -764.536% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -921.01% |
| Laurus Labs Limited | 83.87 Billion INR | 81.634% |
| Lupin Limited | 239.97 Billion INR | 93.581% |
| Mankind Pharma Limited | 119.63 Billion INR | 87.124% |
| Medicamen Biotech Limited | 2.94 Billion INR | -423.011% |
| Medico Remedies Limited | 961.95 Million INR | -1501.309% |
| Megasoft Limited | 3.65 Billion INR | -320.985% |
| NATCO Pharma Limited | 69.06 Billion INR | 77.696% |
| Piramal Pharma Limited | 153.11 Billion INR | 89.94% |
| RPG Life Sciences Limited | 5.12 Billion INR | -200.346% |
| Sigachi Industries Limited | 6.94 Billion INR | -121.907% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 98.198% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 31.663% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -280.658% |
| Unichem Laboratories Limited | 31.69 Billion INR | 51.397% |
| Wanbury Limited | 3.43 Billion INR | -348.447% |
| Windlas Biotech Limited | 6.26 Billion INR | -145.987% |
| ZIM Laboratories Limited | 4.46 Billion INR | -244.742% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 94.739% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -199.08% |
| Divi's Laboratories Limited | 154.7 Billion INR | 90.043% |
| Hester Biosciences Limited | 6.62 Billion INR | -132.565% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -93.915% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -319.871% |
| Bal Pharma Limited | 3.2 Billion INR | -380.786% |
| Strides Pharma Science Limited | 58.39 Billion INR | 73.622% |
| Venus Remedies Limited | 6.26 Billion INR | -145.742% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 40.344% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 29.697% |
| Shilpa Medicare Limited | 30.93 Billion INR | 50.201% |
| Aarti Drugs Limited | 24.32 Billion INR | 36.671% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 31.368% |
| Suven Life Sciences Limited | 2.84 Billion INR | -440.67% |
| Ind-Swift Limited | 6.54 Billion INR | -135.363% |
| Valiant Laboratories Limited | 3.42 Billion INR | -349.501% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 61.434% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | 34.479% |
| Themis Medicare Limited | 5.66 Billion INR | -171.953% |
| Hikal Limited | 24.87 Billion INR | 38.066% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 89.772% |
| Novartis India Limited | 9.24 Billion INR | -66.541% |
| Wockhardt Limited | 76.49 Billion INR | 79.862% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 86.662% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -3171.656% |
| Neuland Laboratories Limited | 18.32 Billion INR | 15.944% |
| Morepen Laboratories Limited | 12.93 Billion INR | -19.114% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -541.662% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -361.989% |